SINGAPORE, June 12, 2019 - (Antara/ACN Newswire) - SGX-listed Singapore eDevelopment Ltd (SeD; SGX:40V) wishes to announce that its U.S. biomedical subsidiary, Global BioLife Inc., has independently tested a new mosquito repellent formula which performs well against mosquitos for six (6) to eight (8) hours.
In 2017, SeD announced a collaboration between Global BioLife and U.S. based Chemia Corporation to develop a suite of fragrances referred to as 3F (Functional Fragrance Formulation). Previous testing was promising for the 3F Mosquito Fragrance, which is made of specialised oils sourced from botanicals that mosquitoes avoid in varying concentrations of 0.25% to 5%.
Global BioLife contracted U.S. based Snell Scientifics, LLC in Meansville, Georgia to conduct a study on the new mosquito repellent formula and the results of the study showed that it repelled between 82% to 95% of mosquitos for six (6) hours after application.
"Utilising fragrances to repel mosquitos with this level of efficacy is a game changer for the consumer products industry," said Mr. Thomas A. Meyer, Chemia's Vice-President of Innovation and Sustainability.
Globally, an estimated 3.4 billion people in 92 countries are at risk of being infected with Zika, Dengue, West Nile Virus, Malaria and other mosquito transmitted diseases. Mosquito repellent products are key in the fight against mosquito transmitted diseases, while a product favoured by consumers is easy to apply, is considered safe, and does not have unpleasant attributes such as a strong chemical odour.
The market for safe mosquito repellents is expanding, and consumers have expressed a demand for effective mosquito repellent products with appealing scents. The most recently tested product has a fragrance that is modeled on the fresh scent of the Ghost Orchid, a rare flower known for its distinctive and pleasant aroma found in the Everglades of Florida.
"3F Mosquito works differently from traditional insect repellents. It's effective even at very low concentrations due to its multi-aspect receptor inhibition," said Mr. Daryl Thompson, Global BioLife's Director of Scientific Initiatives.
"Global BioLife is extremely proud of these test results," said SeD's Executive Chairman Mr. Chan Heng Fai. "3F is an innovative product that works in an entirely different manner from any other product on the market today. 3F is a true success for people everywhere and will help reduce the number of mosquito transmitted diseases on a global scale."
Global BioLife is currently in discussions with interested companies for potential licensing and global deployment of this new mosquito repellent formula.
About Singapore eDevelopment Limited
Incorporated on 9 September 2009 and listed on the Singapore Exchange in July 2010, Singapore eDevelopment Limited is involved in (i) property development and investments primarily in the United States and Western Australia; (ii) information technology-related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities. For more information, please visit: www.SeD.com.sg or email email@example.com.
About Global BioLife Inc.
Global BioLife Inc. ("GBLI") is a 70%-held direct subsidiary of Global BioMedical Inc., which is a wholly-owned direct subsidiary of Singapore BioMedical Pte. Ltd., which in turn is a wholly-owned direct subsidiary of Singapore eDevelopment Limited, a company listed on the Singapore Exchange. The remaining shareholding of Global BioLife Inc. is held by Global Research and Discovery Group Scientific LLC ("GRDGS") at 20% and Australian Exchange-listed Holista CollTech Limited ("Holista") at 10%. For more information, please visit: http://www.globalbiolife.com.
About GRDG Sciences, LLC.
GRDG Sciences, LLC is an advanced research team formed in Florida by natural products discovery drug research scientist, Daryl Thompson. For more information, please visit: http://www.globalrdg.com.